IXICO (IXI.L) Stock Price
IXICO Price
Revenue has compounded at 6.8% per year over the past 19 years to 6.53 M GBP. Earnings per share have declined at 13.9% per year over the last 9 years. IXICO's net margin stands at -25.3%, down from 16.5% several years earlier. Analysts set a median price target of 26.52 GBP, implying 32,245.4% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
IXICO stock price
IXICO business model & stock analysis
Frequently asked questions about IXICO
IXICO PLC is a leading provider of digital technologies in healthcare, specializing in the application of artificial intelligence and data analytics to neurology. Their business model revolves around pioneering digital biomarkers and delivering innovative software solutions to biopharmaceutical and healthcare companies worldwide. IXICO PLC's unique platform allows for the collection, analysis, and interpretation of imaging and wearable sensor data, enabling efficient and accurate evaluation of neurodegenerative diseases. With a strong focus on research and development, IXICO PLC aims to provide valuable insights and assist in the development of new treatments for neurological disorders.
IXICO PLC is primarily active in the healthcare and pharmaceutical industries.
The main competitors of IXICO PLC in the market include companies such as Biogen Inc., Evidera, and ICON plc.
IXICO PLC is a leading provider of digital technologies to the global pharmaceutical industry. Established in 2004, IXICO's expertise lies in utilizing artificial intelligence and machine learning to derive valuable insights from medical imaging and digital biomarker data. The company specializes in providing clinical trial services and neuroimaging analysis solutions, enabling efficient and accurate assessment of neurodegenerative diseases. With a strong focus on research and development, IXICO's innovative technologies have been employed in several clinical trials worldwide. Over the years, IXICO has earned a reputation for its cutting-edge solutions, contributing significantly to advancements in precision medicine.
IXICO PLC has achieved several significant milestones. Notably, the company has made considerable progress in the field of data analytics and biomarker services for neuroscience clinical trials. IXICO PLC has successfully developed and validated novel algorithms and software platforms that provide accurate and reliable biomarker measurements. Additionally, the company has established strong partnerships with leading pharmaceutical and biotech companies, providing them with valuable insights and support in their research and development efforts. Moreover, IXICO PLC has consistently demonstrated its commitment to innovation and excellence, earning recognition and accolades from the industry.
IXICO PLC is primarily present in the United Kingdom, the United States, and Europe.
IXICO PLC represents core values of innovation, scientific excellence, and data-driven solutions in the field of data analytics for neuroscience. The company upholds a corporate philosophy focused on enhancing clinical research outcomes through advanced technology and specialized expertise. By leveraging its proprietary imaging and digital biomarker platform, IXICO PLC enables pharmaceutical companies and research organizations to better understand diseases affecting the brain. Their commitment to reliable and high-quality data analysis supports the development of novel treatments and therapies. With a strong emphasis on collaboration and continuous improvement, IXICO PLC strives to make a meaningful impact in neuroscience research and contribute to improving patients' lives.
Analysts currently set an average price target of 26.52 GBP for the IXICO stock (median: 26.52 GBP), implying +223.5 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the IXICO stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect IXICO to generate revenue of 8.00 M GBP and earnings per share of -0.00 GBP.
Converted at the current exchange rate, the IXICO share trades at 0.10 EUR (0.08 GBP).
The IXICO share (IXI.L) is listed on 4 stock exchanges, including: London (IXI.L), Frankfurt (PYPB.F).
IXICO PLC is a company specialized in digital health, with a business model that aims to offer innovative solutions for supporting clinical trials and diagnosing neurological diseases. The company is divided into different divisions, each offering specific products and services. The first division of IXICO is contract research. The company provides a comprehensive range of services to support companies in conducting clinical trials. This includes brain imaging, quantitative data analysis, and statistical evaluation of studies. Customers such as pharmaceutical and biotech companies can benefit from the company's expertise to evaluate the effectiveness of drugs and optimize study designs. Another division of IXICO is software solutions. The company develops and markets a wide range of software products aimed at supporting the diagnosis and monitoring of neurodegenerative diseases. The product range includes automated image analysis tools and algorithms for analyzing data obtained from neurological imaging techniques such as MRI and CT. Another division of the company is the provision of clinical trials to patients, as well as medical education. IXICO offers expertise and support in study design, decision-making, and the conduct of clinical trials. This can include training sessions and educational materials. The company primarily specializes in neurological diseases, such as multiple sclerosis, Alzheimer's, stroke, and Parkinson's. However, applications for diagnosing diseases affecting the nervous system are also a focus of the company. Overall, IXICO brings together a wealth of expertise that is crucial in the research, diagnosis, and treatment of neurological diseases. This includes scientific expertise in imaging techniques and statistics, as well as a comprehensive range of software products aimed at diagnosing neurological diseases more accurately and quickly. The company is dedicated to contributing to better treatment for patients worldwide and advancing medicine in the field of neurological diseases.
The expected revenue of IXICO is 8.00 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of IXICO is -12,525.13 GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IXICO is currently -606.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IXICO stock.
The price-to-sales ratio (P/S) of IXICO is currently 0.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IXICO stock.
The Eulerpool Quality Score for IXICO is 2/10.
The ISIN of IXICO is GB00BFXR4C20. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IXICO is A2N478. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IXICO is IXI.L. The ticker symbol is used to trade IXICO shares on the stock exchange.
IXICO stock
IXICO Peer Group
IXICO Ticker
IXICO FIGI
All fundamentals and in-depth analysis of IXICO
Our stock analysis for IXICO stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IXICO. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.